Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Operations (2016 - 2025)

Coherus Oncology's Cash from Operations history spans 13 years, with the latest figure at 19716000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 168.92% year-over-year to 19716000.0; the TTM value through Dec 2025 reached 138513000.0, down 577.66%, while the annual FY2025 figure was 138513000.0, 577.66% down from the prior year.
  • Cash from Operations for Q4 2025 was 19716000.0 at Coherus Oncology, up from 46339000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 59734000.0 in Q2 2024 and bottomed at 99953000.0 in Q4 2022.
  • The 5-year median for Cash from Operations is 42627000.0 (2023), against an average of 30619650.0.
  • The largest annual shift saw Cash from Operations crashed 26515.43% in 2022 before it soared 321.13% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 52322000.0 in 2021, then crashed by 91.03% to 99953000.0 in 2022, then surged by 87.06% to 12937000.0 in 2023, then skyrocketed by 321.13% to 28608000.0 in 2024, then tumbled by 168.92% to 19716000.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Cash from Operations are 19716000.0 (Q4 2025), 46339000.0 (Q3 2025), and 46632000.0 (Q2 2025).